JJ,
The company you referred to, GNE:
cbs.marketwatch.com
is actually a different one than discussed in the past. The other similar sounding one was Genzyme Tissue Repair. I wouldn't totally call them competitors, as they are still too far apart in what they're doing, although they are with the current bioengineered knee cartilage treatment available. The GNE news likely has nothing to do with the recent ATIS move.
Unfortunately, it looks like tomorrow won't be a pleasant all-around market day, primarily because of the techs...already getting pounded overseas, with CPQ being no small contributor. If techs lose their hold on the market, it could lead to a sizeable downdraft, but then sector rotation would go with it. Biotechs have already been pounded, so I doubt those that have already been clobbered over the last year are likely to be hurt much tomorrow. Anyway, it's all just heresay until we say the market situation plays out. ATIS, on the other hand, continues to be making progress, slowly but surely, in its fundamental growth.
Hope all is well.
Marshall |
